RENMICE
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

RENMICE Trademark

Serial Number: 79329198 • Registration: 7490473

RENMICE is a trademark filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. on October 20, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (12 trademarks)

No.12, Baoshen South Street,

Entity Type: 03

Trademark Details

Filing Date

October 20, 2021

Registration Date

September 3, 2024

Published for Opposition

June 18, 2024

Goods & Services

Medicines for human purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; diagnostic preparations for medical and veterinary purposes; biological preparations for medical purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; active pharmaceutical ingredients, namely, antibodies for the treatment of human and animal diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of cancer; biochemical medicines for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; vaccines; dietetic preparations adapted for medical use; medicines for veterinary purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases

Filing History

GENERIC MADRID TRANSACTION SENT TO IB
Feb 15, 2025 XXSS
GENERIC MADRID TRANSACTION CREATED
Feb 15, 2025 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 3, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 3, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 3, 2024 R.PR
NOTIFICATION PROCESSED BY IB
Jul 20, 2024 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 18, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 18, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 11, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 11, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 29, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 15, 2024 CNSA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Apr 2, 2024 GPRN
PRIORITY ACTION E-MAILED
Apr 2, 2024 GPRA
PRIORITY ACTION WRITTEN
Apr 2, 2024 CPRA
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 25, 2024 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sep 21, 2023 RCSC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 12, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 24, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
May 24, 2023 OPNR
NEW REPRESENTATIVE AT IB RECEIVED
Mar 28, 2023 NREP
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 24, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 24, 2023 GNSL
SUSPENSION LETTER WRITTEN
Mar 24, 2023 CNSL
DIVISIONAL PROCESSING COMPLETE
Mar 23, 2023 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 23, 2023 AITU
DIVISIONAL REQUEST RECEIVED
Mar 1, 2023 DRRR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 1, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 1, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 1, 2023 TROA
TEAS REQUEST TO DIVIDE RECEIVED
Mar 1, 2023 ERTD
REFUSAL PROCESSED BY IB
Sep 27, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 3, 2022 RFCS
REFUSAL PROCESSED BY MPU
Sep 3, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 1, 2022 RFCR
NON-FINAL ACTION WRITTEN
Jul 31, 2022 CNRT
ASSIGNED TO EXAMINER
Jul 27, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 7, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 3, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 23, 2021 REPR